MedPath

A Study Promoting the Influenza Response in the Elderly

Phase 1
Conditions
The trial is aimed to improve the efficiency of the seasonal influenza vaccine. Healthy volunteers who are positive for cytomegalovirus (CMV) will be recruited and given anti-viral treatment. We hypothesise that this will reduce their viral load and thereby reduce the proportion of T cells committed to CMV. This will then facilitate the development of an optimal response against the influenza vaccine.
Registration Number
EUCTR2011-000092-13-GB
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Inclusion criteria will be aged 65 years or above, CMV seropositive, a T cell response of over 0.5% at randomisation, relevant HLA-type, good renal function (eGFR>50ml/min).
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

Exclusion criteria will include unable to provide consent, on medication that may alter immune function, significant chronic illness as assessed by clinical team as this could affect ability to cooperate with the trial and may alter immune competence, history of a cardiovascular event in the past 6 months, and if the GP considers inappropriate to take part.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath